Management of Philadelphia chromosome-positive acute lymphoblastic leukemia

Por Ottmann, O G
Publicado no Leukemia Suppl (2012)

Phase I Study of INNO-406, a Dual Abl/Lyn Kinase Inhibitor, in Philadelphia Chromosome-Positive Leukemias Post-Imatinib Resistance or Intolerance

Por Kantarjian, H., le Coutre, P., Cortes, J., Pinilla-Ibarz, J., Nagler, A., Hochhaus, A., Kimura, S., Ottmann, O.
Publicado em 2010

Plastic CD34 and CD38 expression in adult B–cell precursor acute lymphoblastic leukemia explains ambiguity of leukemia-initiating stem cell populations

Por Lang, F, Wojcik, B, Bothur, S, Knecht, C, Falkenburg, J H F, Schroeder, T, Serve, H, Ottmann, O G, Rieger, M A
Publicado no Leukemia (2017)

A phase I trial of the trifunctional anti Her2 × anti CD3 antibody ertumaxomab in patients with advanced solid tumors

Por Haense, N., Atmaca, A., Pauligk, C., Steinmetz, K., Marmé, F., Haag, G. M., Rieger, M., Ottmann, O. G., Ruf, P., Lindhofer, H., Al-Batran, S.-E.
Publicado no BMC Cancer (2016)

Phase I/II study of the deacetylase inhibitor panobinostat after allogeneic stem cell transplantation in patients with high-risk MDS or AML (PANOBEST trial)

Por Bug, G, Burchert, A, Wagner, E-M, Kröger, N, Berg, T, Güller, S, Metzelder, S K, Wolf, A, Hünecke, S, Bader, P, Schetelig, J, Serve, H, Ottmann, O G
Publicado no Leukemia (2017)

Differential expression of miR-17∼92 identifies BCL2 as a therapeutic target in BCR-ABL-positive B-lineage acute lymphoblastic leukemia

Por Scherr, M, Elder, A, Battmer, K, Barzan, D, Bomken, S, Ricke-Hoch, M, Schröder, A, Venturini, L, Blair, H J, Vormoor, J, Ottmann, O, Ganser, A, Pich, A, Hilfiker-Kleiner, D, Heidenreich, O, Eder, M
Publicado em 2014